245 related articles for article (PubMed ID: 19195932)
1. Rituximab treatment in a patient with severe thyroid-associated ophthalmopathy: effects on orbital lymphocytic infiltrates.
Salvi M; Vannucchi G; Campi I; Currò N; Simonetta S; Covelli D; Pignataro L; Guastella C; Rossi S; Bonara P; Dazzi D; Ratiglia R; Beck-Peccoz P
Clin Immunol; 2009 May; 131(2):360-5. PubMed ID: 19195932
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of rituximab treatment for thyroid-associated ophthalmopathy as a result of intraorbital B-cell depletion in one patient unresponsive to steroid immunosuppression.
Salvi M; Vannucchi G; Campi I; Rossi S; Bonara P; Sbrozzi F; Guastella C; Avignone S; Pirola G; Ratiglia R; Beck-Peccoz P
Eur J Endocrinol; 2006 Apr; 154(4):511-7. PubMed ID: 16556712
[TBL] [Abstract][Full Text] [Related]
3. New immunomodulators in the treatment of Graves' ophthalmopathy.
Salvi M; Vannucchi G; Campi I; Currò N; Beck-Peccoz P
Ann Endocrinol (Paris); 2008 Apr; 69(2):153-6. PubMed ID: 18417090
[TBL] [Abstract][Full Text] [Related]
4. Treatment of Graves' disease and associated ophthalmopathy with the anti-CD20 monoclonal antibody rituximab: an open study.
Salvi M; Vannucchi G; Campi I; Currò N; Dazzi D; Simonetta S; Bonara P; Rossi S; Sina C; Guastella C; Ratiglia R; Beck-Peccoz P
Eur J Endocrinol; 2007 Jan; 156(1):33-40. PubMed ID: 17218723
[TBL] [Abstract][Full Text] [Related]
5. [New immunomodulators in treatment of Graves'ophtalmopathy].
Josseaume C; Lorcy Y
Ann Endocrinol (Paris); 2008 Sep; 69 Suppl 1():S29-32. PubMed ID: 18954856
[TBL] [Abstract][Full Text] [Related]
6. [Anti-cytokine and anti-lymphocyte monoclonal antibodies in the treatment of thyroid associated ophthalmopathy].
Komorowski J; Jankiewicz-Wika J; Siejka A; Lawnicka H; Stepień H
Pol Merkur Lekarski; 2007 Jun; 22(132):571-4. PubMed ID: 17874632
[TBL] [Abstract][Full Text] [Related]
7. Rituximab induces distinct intraorbital and intrathyroidal effects in one patient satisfactorily treated for Graves' ophthalmopathy.
Bonara P; Vannucchi G; Campi I; Rossi S; Cantoni F; Frugoni C; Sbrozzi F; Guastella C; Avignone S; Beck-Peccoz P; Salvi M
Clin Rev Allergy Immunol; 2008 Feb; 34(1):118-23. PubMed ID: 18270865
[TBL] [Abstract][Full Text] [Related]
8. Rituximab treatment of patients with severe, corticosteroid-resistant thyroid-associated ophthalmopathy.
Khanna D; Chong KK; Afifiyan NF; Hwang CJ; Lee DK; Garneau HC; Goldberg RA; Darwin CH; Smith TJ; Douglas RS
Ophthalmology; 2010 Jan; 117(1):133-139.e2. PubMed ID: 19818507
[TBL] [Abstract][Full Text] [Related]
9. [Radiation therapy for thyroid-associated ophthalmopathy].
Luo QL; He WM; Tang L; Chen LJ
Zhonghua Yan Ke Za Zhi; 2006 Mar; 42(3):218-21. PubMed ID: 16643752
[TBL] [Abstract][Full Text] [Related]
10. Rituximab in the treatment of thyroid eye disease: science fiction?
Salvi M; Vannucchi G; Campi I; Beck-Peccoz P
Orbit; 2009; 28(4):251-5. PubMed ID: 19839884
[TBL] [Abstract][Full Text] [Related]
11. Orbital B-lymphocyte depletion in a treatment failure of rituximab for thyroid eye disease.
Gess AJ; Silkiss RZ
Ophthalmic Plast Reconstr Surg; 2014; 30(1):e11-3. PubMed ID: 23531951
[TBL] [Abstract][Full Text] [Related]
12. Interleukin-2 receptor beta and CD57 expression in orbital tissues from patients with chronic, stable thyroid-associated ophthalmopathy.
Rosen CE; Rizzuto PR; Kennerdell JS; Burde RM; Wall JR
Alaska Med; 1994; 36(4):177-82, 207. PubMed ID: 7531401
[TBL] [Abstract][Full Text] [Related]
13. [Effects of rh-leptin on the proliferation and migration of orbital preadipocytes of thyroid associated ophthalmopathy].
Tang J; Luo QL; He WM
Sichuan Da Xue Xue Bao Yi Xue Ban; 2008 Nov; 39(6):933-5. PubMed ID: 19253829
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of orbital decompression in treatment of thyroid-associated ophthalmopathy: long-term follow-up of 78 patients.
Jernfors M; Välimäki MJ; Setälä K; Malmberg H; Laitinen K; Pitkäranta A
Clin Endocrinol (Oxf); 2007 Jul; 67(1):101-7. PubMed ID: 17466006
[TBL] [Abstract][Full Text] [Related]
15. Long-term multidisciplinary follow-up of unilateral thyroid-associated orbitopathy.
Daumerie Ch; Duprez T; Boschi A
Eur J Intern Med; 2008 Nov; 19(7):531-6. PubMed ID: 19013383
[TBL] [Abstract][Full Text] [Related]
16. [CCR1 expression on immune cells in orbital tissue of patients with thyroid associated ophthalmopathy].
Liu CL; Guo B; Zhang XJ; Lü HB; Tang L; Luo QL
Sichuan Da Xue Xue Bao Yi Xue Ban; 2012 Mar; 43(2):180-2. PubMed ID: 22650026
[TBL] [Abstract][Full Text] [Related]
17. Postural visual obscurations in patients with inactive thyroid eye disease; a variant of 'hydraulic' disease.
Rose GE
Eye (Lond); 2006 Oct; 20(10):1178-85. PubMed ID: 17019416
[TBL] [Abstract][Full Text] [Related]
18. Direct orbital manometry in patients with thyroid-associated orbitopathy.
Riemann CD; Foster JA; Kosmorsky GS
Ophthalmology; 1999 Jul; 106(7):1296-302. PubMed ID: 10406609
[TBL] [Abstract][Full Text] [Related]
19. Evidence of orbital B and T cell depletion after rituximab therapy in Graves' ophthalmopathy.
Nielsen JF; El Fassi D; Nielsen CH; Hegedüs L; Lauer SA; Silkiss RZ; Prause JU
Acta Ophthalmol; 2009 Nov; 87(8):927-9. PubMed ID: 19785644
[No Abstract] [Full Text] [Related]
20. Potential utility of rituximab for Graves' orbitopathy.
Salvi M; Vannucchi G; Beck-Peccoz P
J Clin Endocrinol Metab; 2013 Nov; 98(11):4291-9. PubMed ID: 24009135
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
